Search

Displaying results 3661 - 3670 of 8575 in total
  1. Drug

    Octopamine

    go.drugbank.com/drugs/DB13251
    Experimental

    It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.

  2. Drug

    Domiphen

    go.drugbank.com/drugs/DB11594
    Approved

    Domiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.

  3. Drug

    Framycetin

    go.drugbank.com/drugs/DB00452
    ApprovedInvestigational

    A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

  4. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  5. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  6. Drug

    Bicuculline

    go.drugbank.com/drugs/DB11562
    Experimental

    It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.

  7. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.

  8. Drug

    Buformin

    go.drugbank.com/drugs/DB04830
    ApprovedWithdrawn

    It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis.

  9. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    Polihexanide, also known as polyhexamethylene biguanide (PHMB), is a broad-spectrum antimicrobial polymer primarily used for topical antisepsis and wound management. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]

  10. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.